youtube_live
Q1 2026 tulu • välja lastud • Aktsiakasumit ei saavutatud −1,62% • Tulu ei saavutatud −23,99%
Vaadake tulemusichevron_right
BNTX:NASDAQ
BioNTech SE - ADR
93,02 $
arrow_downward
−2,35%(−2,24) 1 p
93,09 $
arrow_upward
+0,08% (+0,070)bedtimePärast tööaega
Suletud: 7. mai, 16:00:01 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse BNTX põhistatistika genereerimine…
Ava
95,76 $
Kõrge
97,73 $
Madal
92,11 $
Turu kapit.
23,52 mld
Keskm. maht
871,80 tuh
Maht
1,12 mln
52 näd kõrgeim
123,98 $
52 näd madalaim
79,52 $
Aktsiatulu
−5,50 $
Beeta
1,34
Käibivad aktsiad
252,88 mln
Töötajate arv
8 tuh
Uudised
Erinevatest veebiallikatest
AD HOC NEWS
·
5 tunni eest
BioNTech’s $1 Billion Share Buyback Begins as Factory Closures and Founder Exit Reshape the Group
Facebook
·
7 tunni eest
DW News. . BioNTech's vaccine protected millions against COVID-19. Now the company is shrinking fast and betting on cancer research. What happened? #dwbusiness
TipRanks
·
8 tunni eest
BioNTech Launches $1 Billion ADS Buyback to Support Long-Term Growth Strategy
Quiver Quantitative
·
11 tunni eest
BioNTech SE Authorizes $1.0 Billion Share Repurchase Program to Enhance Capital Efficiency and Support Long-Term Value Creation
Profiil
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Teave üksuse BioNTech SE - ADR kohta
AI genereeritud sisu võib sisaldada vigu. Lisateave